Bayer Aktienges ADR (BAYRY)

$8.76 -0.10 (-1.13%)
Market Cap 34.42B
Revenue (ttm) 50.43B
Net Income (ttm) -2.76B
EPS (ttm) N/A
PE Ratio 6.11
Forward PE 6.33
Profit Margin -5.48%
Debt to Equity Ratio 1.26
Volume 342,800
Avg Vol 423,728
Day's Range N/A - N/A
Shares Out 3.93B
Stochastic %K 90%
Beta 0.84
Analysts Sell
Price Target $9.45

Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 49 214 30 1
Address:
Kaiser-Wilhelm-Allee 1, Leverkusen, Germany
profitraider
profitraider Nov. 24 at 7:18 PM
$BAYRY Gimme Fiddy ✌️
0 · Reply
Smartinvestor79
Smartinvestor79 Nov. 24 at 3:48 PM
$BAYRY won't sell a single share below 20.
1 · Reply
EarlyBirdEmail
EarlyBirdEmail Nov. 24 at 11:45 AM
$ADA.X $BAYRY The recent performance of bonds and how investors should work with bonds right now are two topics discussed in a new episode of the Early Bird podcast. https://www.earlybird.email/p/why-bonds-are-suddenly-booming
0 · Reply
HereForFunsies
HereForFunsies Nov. 24 at 11:08 AM
$BAYRY most noise I've seen on this board 🎉🎉 let's go y'all! Congratulations again to everyone who's been holding here!
0 · Reply
GeeKar
GeeKar Nov. 24 at 9:36 AM
$BAYRY finally some good news Bayer stroke drug seen generating €3 bln sales after trial success; stock up 8% https://www.investing.com/news/stock-market-news/bayer-stroke-drug-seen-generating-3-bln-sales-after-trial-success-stock-up-8-4374373
0 · Reply
kubbubsu
kubbubsu Nov. 24 at 8:39 AM
$BAYRY "Stroke is the second leading cause of death globally, and recurrent ischemic strokes tend to be more disabling and carry a higher mortality risk than the first stroke" - can you imagine- finally a break trough!
1 · Reply
kubbubsu
kubbubsu Nov. 24 at 8:34 AM
$BAYRY
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 1:46 AM
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt $BAYRY https://stocktwits.com/news/equity/markets/bayer-stock-fuels-hyper-bullish-retail-mood-after-confirming-new-stroke-study-met-key-goals-following-2023-halt/cL5GryuREfQ
0 · Reply
AlertsAndNews
AlertsAndNews Nov. 23 at 10:55 PM
$BAYRY Bayer’s Asundexian Meets Primary Endpoints in Phase III OCEANIC-STROKE Trial Bayer reported that asundexian met both primary efficacy and safety endpoints in the Phase III OCEANIC-STROKE study for secondary stroke prevention. The treatment, combined with antiplatelet therapy, showed superiority over placebo by significantly reducing ischemic stroke risk without increasing ISTH major bleeding.
0 · Reply
Lifestaylaluxuryy
Lifestaylaluxuryy Nov. 23 at 8:13 PM
$ASBP 🚑 2-minute acting aspirin? Doesn’t exist! ASBP’s sublingual aspirin works 2x faster in the lab. A true medical revolution. 💊⚡ 🧠 Why are the big players freaking out? Bayer, Pfizer, Lilly, J&J → 100 years of aspirin sales, but none have this speed. If ASBP hits the market: 🔥 Their markets collapse 🔥 Patent advantages vanish 🔥 Products go obsolete 🔥 Forced to chase the tech 💥 CEO holds 10M+ shares, critical meetings at CPHI. This little beast will shake the giants! ⏱ Fast Track status + massive showdown = $15–50B potential even at the table. “Whoever grabs it first, leads. $BAYRY $PFE $LLY
1 · Reply
Latest News on BAYRY
No data available.
profitraider
profitraider Nov. 24 at 7:18 PM
$BAYRY Gimme Fiddy ✌️
0 · Reply
Smartinvestor79
Smartinvestor79 Nov. 24 at 3:48 PM
$BAYRY won't sell a single share below 20.
1 · Reply
EarlyBirdEmail
EarlyBirdEmail Nov. 24 at 11:45 AM
$ADA.X $BAYRY The recent performance of bonds and how investors should work with bonds right now are two topics discussed in a new episode of the Early Bird podcast. https://www.earlybird.email/p/why-bonds-are-suddenly-booming
0 · Reply
HereForFunsies
HereForFunsies Nov. 24 at 11:08 AM
$BAYRY most noise I've seen on this board 🎉🎉 let's go y'all! Congratulations again to everyone who's been holding here!
0 · Reply
GeeKar
GeeKar Nov. 24 at 9:36 AM
$BAYRY finally some good news Bayer stroke drug seen generating €3 bln sales after trial success; stock up 8% https://www.investing.com/news/stock-market-news/bayer-stroke-drug-seen-generating-3-bln-sales-after-trial-success-stock-up-8-4374373
0 · Reply
kubbubsu
kubbubsu Nov. 24 at 8:39 AM
$BAYRY "Stroke is the second leading cause of death globally, and recurrent ischemic strokes tend to be more disabling and carry a higher mortality risk than the first stroke" - can you imagine- finally a break trough!
1 · Reply
kubbubsu
kubbubsu Nov. 24 at 8:34 AM
$BAYRY
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 1:46 AM
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt $BAYRY https://stocktwits.com/news/equity/markets/bayer-stock-fuels-hyper-bullish-retail-mood-after-confirming-new-stroke-study-met-key-goals-following-2023-halt/cL5GryuREfQ
0 · Reply
AlertsAndNews
AlertsAndNews Nov. 23 at 10:55 PM
$BAYRY Bayer’s Asundexian Meets Primary Endpoints in Phase III OCEANIC-STROKE Trial Bayer reported that asundexian met both primary efficacy and safety endpoints in the Phase III OCEANIC-STROKE study for secondary stroke prevention. The treatment, combined with antiplatelet therapy, showed superiority over placebo by significantly reducing ischemic stroke risk without increasing ISTH major bleeding.
0 · Reply
Lifestaylaluxuryy
Lifestaylaluxuryy Nov. 23 at 8:13 PM
$ASBP 🚑 2-minute acting aspirin? Doesn’t exist! ASBP’s sublingual aspirin works 2x faster in the lab. A true medical revolution. 💊⚡ 🧠 Why are the big players freaking out? Bayer, Pfizer, Lilly, J&J → 100 years of aspirin sales, but none have this speed. If ASBP hits the market: 🔥 Their markets collapse 🔥 Patent advantages vanish 🔥 Products go obsolete 🔥 Forced to chase the tech 💥 CEO holds 10M+ shares, critical meetings at CPHI. This little beast will shake the giants! ⏱ Fast Track status + massive showdown = $15–50B potential even at the table. “Whoever grabs it first, leads. $BAYRY $PFE $LLY
1 · Reply
abubnic
abubnic Nov. 23 at 5:11 PM
$BAYRY Bayer reports positive results for blood thinner after 2023 setback.
0 · Reply
samsha1
samsha1 Nov. 23 at 3:10 AM
$SLS 🐂 Biomarker Blueprint: Why Sevabertinib’s Approval Matters The FDA just granted accelerated approval to Sevabertinib ($BAYRY) for HER2+ lung cancer based on a 71% ORR and a required companion diagnostic. This validates the exact strategy Sellas is executing. The Comparison: • Sevabertinib (Approved ✅): 71% ORR in HER2+ patients • SLS009 (Phase 2): 100% ORR in ASXL1-mutated AML at the optimal dose The Advantage: Sevabertinib mandates a complex proprietary test (Oncomine Dx). SLS009’s biomarker (ASXL1) is standard in AML panels, and Sellas has filed for patent protection on this diagnostic method. The Setup: The FDA rewards strong efficacy in biomarker-driven niches. SLS009 has Fast Track status and higher response data (100% vs 71%). With ASH 2025 (Dec 6–9) coming, if the ASXL1 data holds, the path to accelerated approval is wide open. Sevabertinib proved the model; SLS has the stronger numbers. 🧬🚀
0 · Reply
Quantumup
Quantumup Nov. 20 at 1:40 PM
Evercore ISI🏁 $ORIC Outperform/$25 $PFE $BAYRY - $ORINY $JNJ Evercore ISI in its initiation report said:
0 · Reply
TalkMarkets
TalkMarkets Nov. 19 at 1:40 PM
5 Companies Leading Agriculture’s Digital Twin Revolution And Why Investors Should Pay Attention $IBM $MSFT $ICL $BAYRY https://talkmarkets.com/content/stocks--equities/5-companies-leading-agricultures-digital-twin-revolution-and-why-investors-should-pay-attention?post=538751&userid=166882
0 · Reply
AanoldMcFace
AanoldMcFace Nov. 18 at 8:12 AM
$BAYRY ah yes, tech is in a bubble and this sells off like there is no tomorrow
1 · Reply
HereForFunsies
HereForFunsies Nov. 17 at 9:31 PM
$BAYRY dang who got that after hours pick up? Lol
0 · Reply
HereForFunsies
HereForFunsies Nov. 17 at 2:19 PM
$BAYRY why retest 8? How about retesting 9 instead?!
0 · Reply
11thestate
11thestate Nov. 14 at 4:32 PM
$BAYRY has agreed to settle with investors over claims that it misled them about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation. Who’s eligible? Anyone who purchased $BAYRY shares between May 23, 2016 and July 6, 2020. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.23 — but if only ~25% of eligible investors file, the effective payout could increase to $0.92. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/bayer-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=11142025
0 · Reply
HereForFunsies
HereForFunsies Nov. 14 at 12:16 PM
$BAYRY jeez, I take it back 😬
1 · Reply
HereForFunsies
HereForFunsies Nov. 13 at 4:45 PM
$BAYRY thanks for offsetting the tech losses today 🫡
1 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:28 PM
$RADX TRP Target Selection & Drug Design Summit 2026 (February 24–26, Boston, MA) - Over three days, experts from Novartis, Bayer, Abdera, Radiopharm Theranostics, AstraZeneca, OncoOne, PentixaPharm, Bicycle Therapeutics, Université Laval $BAYRY $NVS $BCYC $AZN
0 · Reply
HereForFunsies
HereForFunsies Nov. 12 at 4:18 PM
$BAYRY 👀
0 · Reply